Capecitabine Zentiva: Uses, Dosage & Side Effects
An oral fluoropyrimidine prodrug of 5-fluorouracil used in the treatment of colorectal cancer and breast cancer, designed for tumor-selective activation
Capecitabine Zentiva is a prescription oral chemotherapy medication containing capecitabine, a fluoropyrimidine that is converted to the active anticancer agent 5-fluorouracil (5-FU) primarily within tumor tissue. It is used to treat colorectal cancer (both metastatic and as adjuvant therapy after surgery), metastatic breast cancer, and gastric cancer. The key advantage of capecitabine over traditional intravenous 5-FU is oral administration, which allows treatment at home without the need for continuous infusion pumps or central venous catheters. Capecitabine Zentiva is a generic formulation manufactured by Zentiva, bioequivalent to the originator product Xeloda. It is available as 150 mg film-coated tablets and requires careful dose calculation based on body surface area.
Quick Facts: Capecitabine Zentiva
Key Takeaways
- Capecitabine Zentiva is an oral prodrug that is converted to the anticancer agent 5-fluorouracil (5-FU) preferentially within tumor cells, thanks to the enzyme thymidine phosphorylase which is present at higher concentrations in many solid tumors.
- It is approved for metastatic colorectal cancer, adjuvant colorectal cancer (Dukes C stage after surgery), metastatic breast cancer (when certain other treatments have failed), and can be used in gastric cancer combination regimens.
- DPD (dihydropyrimidine dehydrogenase) testing is strongly recommended before starting treatment, as patients with DPD deficiency face a significantly increased risk of severe, potentially life-threatening toxicity.
- The most common dose-limiting side effects are hand-foot syndrome (palmar-plantar erythrodysaesthesia), diarrhea, nausea, and stomatitis; early reporting of symptoms allows timely dose adjustment to prevent severe toxicity.
- Capecitabine has a clinically critical interaction with warfarin and other coumarin anticoagulants that can cause life-threatening bleeding; INR must be closely monitored if co-administration is necessary.
What Is Capecitabine Zentiva and What Is It Used For?
Capecitabine Zentiva contains the active substance capecitabine, a fluoropyrimidine carbamate that functions as an orally administered prodrug of 5-fluorouracil (5-FU). The development of capecitabine represented a significant advancement in cancer therapeutics because it replaced the need for continuous intravenous 5-FU infusion with a convenient tablet formulation. Since its original approval by the European Medicines Agency and the U.S. Food and Drug Administration, capecitabine has become one of the most widely prescribed oral chemotherapy agents worldwide. Capecitabine Zentiva is a generic version manufactured by Zentiva, demonstrated to be bioequivalent to the originator product.
The innovative design of capecitabine lies in its three-step enzymatic activation pathway, which is engineered to generate higher concentrations of 5-FU within tumor tissue compared to normal healthy tissue. After oral absorption, capecitabine passes through the liver where carboxylesterase converts it to 5'-deoxy-5-fluorocytidine (5'-DFCR). This intermediate is then converted by cytidine deaminase, found primarily in the liver and tumor tissue, to 5'-deoxy-5-fluorouridine (5'-DFUR). The final and critical step involves the enzyme thymidine phosphorylase (TP), which converts 5'-DFUR to the active drug 5-fluorouracil. Thymidine phosphorylase is expressed at significantly higher concentrations in many tumor types compared to corresponding normal tissues, which results in preferential activation of the drug at the tumor site.
Once activated, 5-fluorouracil exerts its anticancer effects through multiple mechanisms. It inhibits thymidylate synthase (TS), an enzyme essential for DNA synthesis and repair, thereby blocking the production of thymidine monophosphate (dTMP) required for DNA replication. Additionally, 5-FU metabolites are incorporated into RNA, disrupting normal RNA processing and protein synthesis. The combined effect of DNA synthesis inhibition and RNA disruption leads to cell cycle arrest and apoptotic cell death in rapidly dividing cancer cells.
Capecitabine is listed on the World Health Organization (WHO) Model List of Essential Medicines, reflecting its importance in global cancer treatment. It is approved for the following therapeutic indications:
- Metastatic colorectal cancer: Capecitabine is used as first-line treatment for metastatic colorectal cancer either as monotherapy or in combination with other anticancer agents such as oxaliplatin (XELOX/CAPOX regimen) or bevacizumab. Multiple randomized controlled trials, including the landmark X-ACT study, have demonstrated that capecitabine provides at least equivalent efficacy to intravenous 5-FU/leucovorin regimens with a more favorable safety profile in certain respects.
- Adjuvant colorectal cancer: Capecitabine is used as adjuvant therapy following surgical resection of stage III (Dukes C) colon cancer. The X-ACT trial demonstrated that capecitabine was at least as effective as intravenous 5-FU/leucovorin in the adjuvant setting, with a trend toward superior disease-free survival. It may also be combined with oxaliplatin in the adjuvant CAPOX regimen.
- Metastatic breast cancer: Capecitabine is approved for metastatic breast cancer in combination with docetaxel after failure of cytotoxic chemotherapy that included an anthracycline, and as monotherapy after failure of taxane-containing and anthracycline-containing chemotherapy, or in patients for whom further anthracycline therapy is not indicated.
- Gastric and gastro-oesophageal junction cancer: Capecitabine is used as part of combination regimens (typically with a platinum-based agent) for the treatment of advanced gastric cancer. The REAL-2 and ML17032 trials demonstrated non-inferiority of capecitabine-based regimens compared to 5-FU-based regimens in this setting.
Colorectal cancer is the third most commonly diagnosed cancer worldwide and the second leading cause of cancer-related death, according to WHO Global Cancer Observatory data. The availability of effective oral chemotherapy such as capecitabine has significantly improved treatment accessibility and patient quality of life by reducing the need for hospitalization and invasive intravenous access devices. Breast cancer is the most common cancer in women globally, and capecitabine provides an important treatment option particularly in the advanced disease setting.
Capecitabine is designed to be selectively activated within tumor tissue through the enzyme thymidine phosphorylase (TP), which is found at 3-10 times higher concentrations in many tumor types compared to adjacent normal tissue. This tumor-selective activation aims to maximize anticancer activity while reducing systemic toxicity compared to intravenous 5-FU. However, 5-FU is still generated systemically to some degree, which accounts for the side effects observed during treatment.
What Should You Know Before Taking Capecitabine Zentiva?
Contraindications
There are specific situations in which Capecitabine Zentiva must not be used. Understanding these absolute contraindications is essential for safe treatment and must be evaluated before the first dose.
- Hypersensitivity: Do not take capecitabine if you have a known hypersensitivity to capecitabine, to 5-fluorouracil, or to any of the excipients in the product. Patients who have experienced severe or unexpected reactions to fluoropyrimidine therapy in the past should not receive capecitabine.
- Complete DPD deficiency: Capecitabine must not be given to patients with known complete absence of dihydropyrimidine dehydrogenase (DPD) activity. DPD is the rate-limiting enzyme responsible for breaking down 5-FU. Complete deficiency leads to dramatically increased exposure to 5-FU and its toxic metabolites, causing life-threatening or fatal toxicity.
- Concurrent sorivudine or brivudine: Capecitabine must not be taken together with sorivudine, brivudine, or their chemically related analogues (nucleoside antiviral agents). These drugs inhibit DPD irreversibly, leading to a marked increase in 5-FU exposure. A minimum 4-week washout period is required after stopping brivudine or sorivudine before capecitabine may be started.
- Severe renal impairment: Capecitabine is contraindicated in patients with severe renal impairment (creatinine clearance below 30 mL/min at baseline).
- Pregnancy and breastfeeding: Capecitabine must not be used during pregnancy. Women of childbearing potential must use effective contraception during treatment and for 6 months after the last dose.
- Severe leukopenia, neutropenia, or thrombocytopenia: Treatment should not be initiated in patients with pre-existing severe bone marrow suppression.
Warnings and Precautions
Dihydropyrimidine dehydrogenase (DPD) deficiency testing is strongly recommended before initiating capecitabine. Approximately 3-8% of the population carries partial DPD deficiency, and rare individuals have complete deficiency. Patients with DPD deficiency who receive standard doses of capecitabine may experience severe, life-threatening, or fatal toxicity including mucositis, diarrhea, neutropenia, and neurotoxicity. Genotyping for DPYD gene variants (such as DPYD*2A, c.2846A>T, c.1679T>G, and c.1236G>A/HapB3) is the recommended testing approach. Patients with partial deficiency require a significant dose reduction. Patients with complete deficiency must not receive capecitabine.
Before and during treatment with Capecitabine Zentiva, your doctor should be informed about and monitor the following conditions:
- Kidney function: Patients with moderate renal impairment (creatinine clearance 30-50 mL/min) require a dose reduction to 75% of the recommended starting dose. Kidney function should be monitored throughout treatment, as deterioration can increase drug exposure and toxicity.
- Liver function: Patients with liver metastases and mild-to-moderate liver impairment should be carefully monitored. Capecitabine can cause hepatic dysfunction including hyperbilirubinaemia. Treatment should be interrupted if treatment-related elevations in bilirubin exceed 3.0 times the upper limit of normal or hepatic aminotransferases exceed 2.5 times the upper limit of normal.
- Cardiovascular disease: Cardiotoxicity, including myocardial infarction, angina, arrhythmias, cardiogenic shock, and sudden death, has been associated with fluoropyrimidine therapy. Patients with a history of coronary artery disease are at increased risk and should be monitored carefully. Capecitabine should be used with caution in patients with a history of significant cardiac disease.
- Diarrhea: Severe diarrhea can be life-threatening. Patients experiencing grade 2 or higher diarrhea (4-6 stools per day above baseline or nocturnal stools) should immediately stop capecitabine and contact their doctor. Standard antidiarrheal treatment (e.g., loperamide) should be started promptly. Dehydration should be corrected aggressively.
- Dehydration: Dehydration from any cause (diarrhea, nausea, vomiting, poor oral intake) can rapidly escalate toxicity because it reduces renal clearance of capecitabine metabolites. Adequate fluid intake must be maintained throughout treatment.
- Hand-foot syndrome: Persistent or severe hand-foot syndrome (palmar-plantar erythrodysaesthesia) requires dose modification. Early intervention with emollients and dose adjustment can prevent progression to debilitating grades.
Pregnancy and Breastfeeding
Capecitabine Zentiva must not be used during pregnancy. In animal studies, capecitabine caused embryolethality and teratogenicity at clinically relevant doses. If pregnancy occurs during treatment, the patient must be informed of the potential hazard to the fetus. Women of childbearing potential must be advised to use effective contraception during treatment and for at least 6 months after the last dose of capecitabine.
Breastfeeding must be discontinued during capecitabine treatment. It is not known whether capecitabine is excreted in human breast milk, but given the serious potential adverse effects on a nursing infant, breastfeeding is contraindicated. Women should not breastfeed during treatment and for 2 weeks after the last dose.
Male patients with female partners of childbearing potential should use effective contraception during treatment and for at least 3 months after the last dose. Capecitabine may impair fertility in both men and women. Patients should be counseled about fertility preservation options before starting treatment.
How Does Capecitabine Zentiva Interact with Other Drugs?
Drug interactions with capecitabine can be pharmacokinetic (affecting how the drug is absorbed, distributed, metabolized, or eliminated) or pharmacodynamic (affecting the drug's therapeutic or toxic effects). Because capecitabine is converted to 5-FU, interactions known to affect 5-FU metabolism or activity are also relevant to capecitabine. Careful medication review before and during treatment is essential.
Major Interactions
| Drug | Interaction | Clinical Action |
|---|---|---|
| Warfarin / Coumarin anticoagulants | Capecitabine dramatically increases the anticoagulant effect, raising INR and risk of fatal bleeding. The mechanism likely involves CYP2C9 inhibition by capecitabine metabolites. | Monitor INR/PT very frequently. Adjust anticoagulant dose. The interaction may occur within days of starting capecitabine or even after stopping it. Consider switching to low-molecular-weight heparin. |
| Sorivudine / Brivudine | Irreversible DPD inhibition leading to massively increased 5-FU exposure and life-threatening toxicity. Fatal cases have been reported. | Absolute contraindication. Must wait at least 4 weeks after stopping brivudine/sorivudine before starting capecitabine. |
| Phenytoin / Fosphenytoin | Increased phenytoin plasma levels leading to potential toxicity. Capecitabine inhibits CYP2C9, the enzyme primarily responsible for phenytoin metabolism. | Monitor phenytoin levels regularly. Dose reduction of phenytoin may be necessary. |
| Leucovorin (Folinic acid) | Leucovorin enhances the cytotoxic effect of 5-FU by stabilizing the 5-FU-thymidylate synthase complex, increasing both efficacy and toxicity. | When used in combination, closely monitor for increased toxicity. Dose adjustment of capecitabine may be required. |
Other Important Interactions
| Drug | Interaction | Clinical Action |
|---|---|---|
| Allopurinol | May reduce the efficacy of capecitabine. Allopurinol can decrease 5-FU activation by inhibiting orotate phosphoribosyltransferase. | Avoid concomitant use with capecitabine if possible. If co-administration is necessary, monitor therapeutic response carefully. |
| Oxaliplatin | Commonly used in combination (CAPOX regimen). Oxaliplatin does not significantly affect capecitabine pharmacokinetics but additive toxicities (especially diarrhea and neuropathy) occur. | Monitor closely for additive toxicities. Dose modifications may be needed based on toxicity grade. |
| Antacids (aluminium/magnesium hydroxide) | Slight increase in capecitabine and its metabolite plasma concentrations when taken with antacids. | Clinically not significant for most patients, but be aware of potential for modestly increased exposure. |
| CYP2C9 substrates | Capecitabine is a CYP2C9 inhibitor. Plasma levels of other CYP2C9 substrates (e.g., NSAIDs, sulfonylureas) may increase. | Use caution with CYP2C9 substrate medications. Monitor for increased effects or toxicity of the co-administered drug. |
In addition to the above interactions, patients should be aware that capecitabine tablets should be taken within 30 minutes after a meal. While food delays absorption slightly, it does not significantly affect overall drug exposure and the recommendation to take with food is primarily to reduce gastrointestinal side effects. Patients should always provide their complete medication list, including over-the-counter drugs, herbal supplements, and vitamins, to their treating oncologist before starting capecitabine.
What Is the Correct Dosage of Capecitabine Zentiva?
Capecitabine dosing requires careful calculation based on the patient's body surface area (BSA). Your oncologist will determine the appropriate number of tablets for you. The 150 mg tablets allow for precise dose adjustments. It is essential to take the correct number of tablets at each dose and to follow the prescribed schedule exactly. Capecitabine tablets should be swallowed whole with water within 30 minutes after finishing a meal (breakfast and evening meal). Tablets should not be crushed, chewed, or broken.
Adults
Monotherapy (Colorectal Cancer / Breast Cancer)
The recommended starting dose is 1,250 mg/m² administered orally twice daily (equivalent to 2,500 mg/m² total daily dose). Treatment is given in 3-week cycles: 14 days of treatment followed by a 7-day rest period. Treatment duration depends on the cancer type and treatment setting: in the adjuvant setting for colon cancer, a total of 8 cycles (24 weeks) is recommended; in the metastatic setting, treatment continues until disease progression or unacceptable toxicity.
Combination with Oxaliplatin (CAPOX/XELOX)
When combined with oxaliplatin for colorectal cancer, the recommended capecitabine dose is 1,000 mg/m² twice daily for 14 days, followed by a 7-day rest period, in 3-week cycles. Oxaliplatin 130 mg/m² is given as an intravenous infusion on day 1 of each cycle. This reduced capecitabine dose when used in combination helps manage additive toxicities.
Combination with Docetaxel (Breast Cancer)
When combined with docetaxel for metastatic breast cancer, the recommended capecitabine dose is 1,250 mg/m² twice daily for 14 days, followed by a 7-day rest period, in 3-week cycles. Docetaxel 75 mg/m² is given as a 1-hour intravenous infusion on day 1 of each cycle. Premedication according to the docetaxel label is required.
Dose Modifications for Toxicity
Dose modifications are critical for managing treatment-related side effects. If a grade 2 or higher toxicity occurs, treatment should be interrupted until the toxicity resolves to grade 0-1. For the first appearance of a grade 2 toxicity, treatment may be resumed at the same dose. For the second appearance of grade 2 or first appearance of grade 3, the dose should be reduced to 75% of the original dose. For the third appearance of grade 2 or second appearance of grade 3, the dose should be reduced to 50%. Permanent discontinuation is recommended for grade 4 toxicity or the fourth appearance of grade 2 toxicity.
Renal Impairment
Renal function must be assessed before starting treatment. For patients with moderate renal impairment (creatinine clearance 30-50 mL/min at baseline), the starting dose should be reduced to 75% of the standard dose (i.e., approximately 950 mg/m² twice daily for monotherapy). Capecitabine is contraindicated in patients with severe renal impairment (creatinine clearance below 30 mL/min). For patients with mild renal impairment (creatinine clearance 51-80 mL/min), no initial dose adjustment is recommended, but kidney function should be monitored during treatment.
Elderly Patients
No specific initial dose adjustment is required solely based on age. However, elderly patients (65 years and older) tend to experience a higher incidence of grade 3-4 adverse reactions compared to younger patients. Careful monitoring is essential in elderly patients, and dose modifications should be applied promptly when toxicity occurs. Some guidelines recommend a starting dose of 1,000 mg/m² twice daily in patients over 70 years of age.
Children
The safety and efficacy of capecitabine in children and adolescents (under 18 years) have not been established. There are no relevant indications for capecitabine use in the pediatric population for the currently approved indications. Capecitabine is not recommended for use in children.
Missed Dose
If you miss a dose of Capecitabine Zentiva, do not take a double dose to make up for the missed one. Skip the missed dose entirely and continue with your next scheduled dose. Taking a double dose increases the risk of serious side effects. Record any missed doses and inform your oncologist at your next visit, as this may affect treatment efficacy.
Overdose
In the event of an overdose, the expected manifestations are exaggerated versions of the known side effects: nausea, vomiting, diarrhea, mucositis, gastrointestinal irritation and bleeding, and bone marrow depression. If an overdose is suspected, treatment should be stopped immediately and supportive care provided. There is no specific antidote for capecitabine overdose. Medical management should include correction of dehydration, monitoring of blood counts, and treatment of any clinical complications. Dialysis is not expected to be effective due to the rapid metabolism of capecitabine.
What Are the Side Effects of Capecitabine Zentiva?
Like all anticancer medications, capecitabine can cause side effects. The severity and frequency of side effects depend on the dose, whether capecitabine is used alone or in combination with other drugs, and individual patient factors including DPD enzyme activity, renal function, and overall health. Most side effects are dose-dependent and can be managed through dose reduction or temporary treatment interruption. It is essential to report all side effects to your oncologist promptly, as early intervention prevents escalation to severe toxicity.
The side effects listed below are based on data from clinical trials and post-marketing surveillance. The frequencies are defined as: Very common (affects more than 1 in 10 patients), Common (affects 1 to 10 in 100 patients), Uncommon (affects 1 to 10 in 1,000 patients), and Rare (affects fewer than 1 in 1,000 patients).
Monotherapy Side Effect Profile
Very Common
- Hand-foot syndrome (palmar-plantar erythrodysaesthesia) — redness, swelling, numbness, tingling, peeling of palms and soles
- Diarrhea — can range from mild loose stools to severe, life-threatening diarrhea requiring hospitalization
- Nausea
- Vomiting
- Stomatitis and oral mucositis — inflammation and sores in the mouth
- Abdominal pain
- Fatigue and asthenia (weakness)
- Decreased appetite (anorexia)
Common
- Neutropenia (low white blood cell count) — increases risk of infection
- Anemia (low red blood cell count)
- Thrombocytopenia (low platelet count)
- Hyperbilirubinemia (elevated bilirubin)
- Dermatitis, skin rash, alopecia (hair thinning)
- Dry skin, nail disorders
- Dyspepsia (indigestion), constipation
- Upper abdominal pain
- Headache, dizziness, lethargy
- Peripheral neuropathy (numbness/tingling in hands and feet)
- Taste disturbances (dysgeusia)
- Eye irritation, increased lacrimation (tearing)
- Pyrexia (fever), edema (swelling)
- Dehydration
Uncommon
- Cardiotoxicity — angina pectoris, myocardial infarction, cardiac arrhythmias, heart failure
- Deep vein thrombosis, pulmonary embolism
- Hepatic dysfunction (liver enzyme elevations)
- Febrile neutropenia (fever with dangerously low white blood cells)
- Severe skin reactions (Stevens-Johnson syndrome has been reported rarely)
- Lacrimal duct stenosis (narrowing of the tear ducts)
- Confusion, cerebellar toxicity (coordination problems)
- Renal impairment
Rare
- Toxic leukoencephalopathy
- Severe hepatotoxicity including hepatic failure
- Pancytopenia (severe suppression of all blood cell lines)
- Anaphylaxis / severe hypersensitivity
- Cutaneous lupus erythematosus
- Corneal disorders
Hand-Foot Syndrome: What to Watch For
Hand-foot syndrome (palmar-plantar erythrodysaesthesia, PPE) is the most characteristic side effect of capecitabine and occurs more frequently with capecitabine than with intravenous 5-FU. It presents in progressive stages:
- Grade 1 (Mild): Numbness, tingling, painless swelling, or mild redness of palms and/or soles. Does not interfere with daily activities. Treatment usually continues at the same dose.
- Grade 2 (Moderate): Painful redness, swelling, or discomfort affecting daily activities. Dose interruption is required until resolution to grade 0-1.
- Grade 3 (Severe): Moist desquamation (peeling), ulceration, blistering, or severe pain making it impossible to work or perform activities of daily living. Dose interruption and reduction are required.
Preventive measures include using emollient creams regularly, avoiding hot water, excessive friction, and tight-fitting shoes, and wearing soft cotton gloves and socks at night. Pyridoxine (vitamin B6) has been studied for prevention, but evidence of benefit is inconsistent and it is not routinely recommended in current guidelines.
Contact your doctor or emergency services immediately if you experience: severe diarrhea (more than 4 episodes per day or nocturnal diarrhea), severe nausea/vomiting preventing adequate fluid intake, fever above 38°C (100.4°F), chest pain or palpitations, sudden severe headache or confusion, severe mouth sores preventing eating or drinking, blood in stools or vomit, or signs of severe dehydration (dizziness, dark urine, rapid heartbeat).
How Should You Store Capecitabine Zentiva?
Proper storage of Capecitabine Zentiva is important to ensure the medication remains effective throughout its shelf life. Film-coated tablets should be stored at a temperature not exceeding 30°C (86°F). Keep the tablets in their original blister packaging or container until the time of use to protect them from moisture and light.
As with all medications, Capecitabine Zentiva should be stored in a secure location out of the reach and sight of children. Chemotherapy medications can be harmful if accidentally ingested by children or other household members. If a household member accidentally takes capecitabine, seek medical attention immediately.
Do not use the medication after the expiry date stated on the carton and blister/container. The expiry date refers to the last day of that month. Do not dispose of capecitabine tablets in household waste or wastewater. As a cytotoxic drug, capecitabine requires special handling and disposal. Return any unused tablets to your pharmacy, where they will be disposed of in accordance with local regulations for the safe disposal of cytotoxic medicines. This helps protect the environment from potentially harmful pharmaceutical waste.
If you notice any visible changes in the appearance of the tablets (such as discoloration, crumbling, or unusual odor), do not take them and consult your pharmacist. Damaged or deteriorated tablets may not provide the correct dose and should be replaced.
What Does Capecitabine Zentiva Contain?
The active substance in Capecitabine Zentiva is capecitabine. Each film-coated tablet contains 150 mg of capecitabine. Capecitabine has the chemical name pentyl [1-(3,4-dihydroxy-5-methyltetrahydrofuran-2-yl)-5-fluoro-2-oxo-1H-pyrimidin-4-yl]aminoformate, with the molecular formula C15H22FN3O6 and a molecular weight of 359.35 g/mol.
The excipients (inactive ingredients) in the tablet core typically include:
- Lactose anhydrous: Used as a filler/diluent to give the tablet adequate bulk.
- Microcrystalline cellulose: A bulking agent and binder that provides structural integrity to the tablet.
- Hypromellose: Used as a binder in the tablet core and as a film-forming agent in the coating.
- Croscarmellose sodium: A disintegrant that helps the tablet break apart in the gastrointestinal tract for proper drug release.
- Magnesium stearate: A lubricant that prevents the tablet from sticking to manufacturing equipment during production.
The film coating typically contains hypromellose, titanium dioxide (E171), talc, and iron oxide pigments (yellow and red, E172) that give the tablet its characteristic light peach color. The film coating serves multiple purposes: it makes the tablet easier to swallow, protects the active ingredient from moisture and light, and masks any unpleasant taste.
Patients with known lactose intolerance should be aware that the tablets contain lactose. Those with rare hereditary problems of galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption should not take this medicine. Inform your doctor or pharmacist if you have any known allergies or intolerances to any of the listed excipients before starting treatment.
Capecitabine Zentiva 150 mg tablets are typically light peach-colored, biconvex, oblong film-coated tablets. They may bear an imprint for identification. The tablets are available in blister packs or bottles, with various pack sizes available depending on the market.
Frequently Asked Questions About Capecitabine Zentiva
Capecitabine Zentiva and Xeloda both contain the same active ingredient, capecitabine, at the same dosage strengths. Xeloda is the original brand-name product developed by Roche, while Capecitabine Zentiva is a generic version manufactured by Zentiva. Generic medications must demonstrate bioequivalence to the originator product through rigorous regulatory testing, meaning they deliver the same amount of active drug to the bloodstream at the same rate. The therapeutic effects, dosing, and side effect profile are the same. The main difference is typically the price, with generic versions generally being more affordable.
There is no specific absolute contraindication against alcohol consumption while taking capecitabine, but it is generally advisable to avoid or strictly limit alcohol intake during treatment. Alcohol can worsen nausea and diarrhea, which are already common side effects of capecitabine. It can also contribute to dehydration, which increases the risk of drug toxicity. Additionally, alcohol may put extra strain on the liver, which is involved in the metabolic activation of capecitabine. Discuss your alcohol consumption with your oncologist for personalized advice.
Capecitabine should be taken within 30 minutes after finishing a meal because this was the administration method used in the pivotal clinical trials that established the drug's efficacy and safety profile. Taking capecitabine with food reduces the rate of absorption slightly, which may help reduce peak plasma levels of the drug and its metabolites, potentially decreasing the severity of gastrointestinal side effects such as nausea and vomiting. The overall exposure (total amount of drug absorbed) is not significantly affected by food, so efficacy is maintained.
Treatment duration varies depending on the cancer type and clinical setting. In the adjuvant setting for colon cancer (after surgery), the standard course is 8 cycles of 3 weeks each, totaling 24 weeks (approximately 6 months). In the metastatic setting (for both colorectal and breast cancer), treatment typically continues until disease progression or until side effects become unacceptable. Some patients may remain on capecitabine for many months or even years if the cancer responds well and the side effects are manageable. Your oncologist will regularly assess whether to continue, modify, or stop treatment based on imaging scans and your tolerance.
If you develop diarrhea during capecitabine treatment, start standard antidiarrheal treatment (such as loperamide) immediately and increase your fluid intake to prevent dehydration. For mild diarrhea (increase of fewer than 4 stools per day), you can continue capecitabine while treating the diarrhea. However, if diarrhea reaches grade 2 or higher (4-6 additional stools per day, nocturnal stools, or diarrhea that interferes with daily activities), you must stop taking capecitabine and contact your oncologist. Do not resume capecitabine until the diarrhea has fully resolved. Severe diarrhea with dehydration can be life-threatening and may require intravenous fluids and hospitalization.
Yes, capecitabine is a chemotherapy medication (cytotoxic anticancer drug). Although it is taken as a tablet at home rather than administered in a hospital via intravenous infusion, it is still a potent chemotherapy agent. It works by being converted into 5-fluorouracil (5-FU), which is one of the oldest and most widely used chemotherapy drugs. Because it is chemotherapy, capecitabine requires the same careful monitoring, handling precautions, and management of side effects as intravenous chemotherapy. Household members should avoid direct contact with broken tablets.
References
This article is based on the following evidence-based sources. All medical claims are supported by peer-reviewed research and current international clinical guidelines:
- European Medicines Agency (EMA). Capecitabine — Summary of Product Characteristics. Updated 2025. European public assessment report.
- U.S. Food and Drug Administration (FDA). Xeloda (capecitabine) Prescribing Information. Updated 2024.
- Twelves C, Wong A, Nowacki MP, et al. Capecitabine as adjuvant treatment for stage III colon cancer. New England Journal of Medicine. 2005;352(26):2696-2704.
- Cassidy J, Clarke S, Díaz-Rubio E, et al. XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results. British Journal of Cancer. 2011;105(1):58-64.
- Henricks LM, Lunenburg CATC, de Man FM, et al. DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis. The Lancet Oncology. 2018;19(11):1459-1467.
- World Health Organization (WHO). Model List of Essential Medicines, 23rd List. Geneva: WHO; 2023.
- European Society for Medical Oncology (ESMO). Clinical Practice Guidelines: Metastatic Colorectal Cancer. Updated 2024.
- National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology: Colon Cancer. Version 1.2025.
- Cunningham D, Starling N, Rao S, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer (REAL-2 trial). New England Journal of Medicine. 2008;358(1):36-46.
- EMA Committee for Medicinal Products for Human Use (CHMP). Assessment Report: DPD testing prior to treatment with fluorouracil, capecitabine, tegafur and flucytosine. 2020.
About Our Medical Editorial Team
This article has been researched, written, and medically reviewed by the iMedic Medical Editorial Team, comprising licensed specialist physicians in oncology and clinical pharmacology. Our team follows strict editorial standards based on international medical guidelines (WHO, EMA, FDA, ESMO, NCCN) and the GRADE evidence framework.
All content is written by medical professionals with expertise in oncology and pharmacology. Information is derived from approved product labeling, peer-reviewed clinical trials, and current international treatment guidelines.
Every article undergoes review by the iMedic Medical Review Board, an independent panel of specialist physicians who verify accuracy, completeness, and adherence to current evidence-based medicine principles.
iMedic has no commercial funding from pharmaceutical companies. Our content is produced independently with no influence from drug manufacturers, ensuring unbiased and objective medical information.
This article is reviewed and updated regularly to reflect the latest evidence, guideline changes, and safety communications from regulatory authorities including the EMA, FDA, and WHO.